Advertisement

Topics

Search Results for "Sjogren A Belimumab"

21:53 EDT 25th June 2017 | BioPortfolio

Matching Channels

None

Matching News

Real-world belimumab reduces disease activity in patients with lupus

Belimumab reduced disease activity and corticosteroid use after 6 months, according to real-world results published in Rheumatology and Therapy.“The OBSErve Germany study provides the first insight ...

GSK invests $139m to increase Benlysta (belimumab) production capacity

GSK is investing $139m in its biopharmaceutical manufacturing site located in Rockville, Maryland, to expand the production of Benlysta (belimumab).

A chance diagnosis of Sjogren’s syndrome heralded the start of Stephen McPhail’s long road to recovery

  All footballers feel lucky to be living the dream but Stephen McPhail appreciates his place on the pitch more than most.Not only has he successfully defeated cancer in the form of non-Hodgkin...

Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Updated: 30052017] Prices from USD $4208

DelveInsight's Sjogren's Syndrome Market Insights, Epidemiology and Market Forecast2023 Reports provides an overview of the disease and global market trends of the Sjogren's Syndrome for the seven ma...

Belimumab plus standard lupus therapy seen as safe, effective over 10 years

MADRID — Belimumab plus standard therapy was safe and effective over 10 years in patients with lupus, according to findings presented at the EULAR Annual Congress. “In lupus, the underlying diseas...

Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome

This study reports the clinical and pathological features of 12 cases of primary Sjogren syndrome (pSS) with renal involvement presenting with proximal tubular dysfunction in a single center, and inve...

Belimumab for Lupus: Helpful in the Real World (CME/CE)

(MedPage Today) -- More than half had improvement of 50% or more at 6 months

Gilead: Don't Buy It Based On Sjogren's Syndrome

Matching PubMed Articles

New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.

Belimumab is currently approved for the treatment of patients with active SLE despite standard treatment. However, it has not been formally tested for patients with lupus nephritis because such patien...

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE). Methods Patients with moderate-to-severe SLE (SELENA-SLEDAI ≥8) were r...

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.

Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimu...

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the ...

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.

To study self-administration and pharmacokinetics (PK) of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE).

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement